These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 11870800)
1. Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Igawa T; Lin FF; Lee MS; Karan D; Batra SK; Lin MF Prostate; 2002 Mar; 50(4):222-35. PubMed ID: 11870800 [TBL] [Abstract][Full Text] [Related]
2. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142 [TBL] [Abstract][Full Text] [Related]
3. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Thalmann GN; Sikes RA; Wu TT; Degeorges A; Chang SM; Ozen M; Pathak S; Chung LW Prostate; 2000 Jul; 44(2):91-103 Jul 1;44(2). PubMed ID: 10881018 [TBL] [Abstract][Full Text] [Related]
4. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045 [TBL] [Abstract][Full Text] [Related]
5. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223 [TBL] [Abstract][Full Text] [Related]
6. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359 [TBL] [Abstract][Full Text] [Related]
7. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase. Igawa T; Lin FF; Rao P; Lin MF Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404 [TBL] [Abstract][Full Text] [Related]
8. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP. Iwasa Y; Mizokami A; Miwa S; Koshida K; Namiki M Int J Urol; 2007 Mar; 14(3):233-9. PubMed ID: 17430262 [TBL] [Abstract][Full Text] [Related]
9. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity. Kokontis JM; Hsu S; Chuu CP; Dang M; Fukuchi J; Hiipakka RA; Liao S Prostate; 2005 Dec; 65(4):287-98. PubMed ID: 16015608 [TBL] [Abstract][Full Text] [Related]
10. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53. Nesslinger NJ; Shi XB; deVere White RW Cancer Res; 2003 May; 63(9):2228-33. PubMed ID: 12727844 [TBL] [Abstract][Full Text] [Related]
11. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Zhao XY; Ly LH; Peehl DM; Feldman D Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780 [TBL] [Abstract][Full Text] [Related]
12. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349 [TBL] [Abstract][Full Text] [Related]
13. Rapid detection of candidate metastatic foci in the orthotopic inoculation model of androgen-sensitive prostate cancer cells introduced with green fluorescent protein. Maeda H; Segawa T; Kamoto T; Yoshida H; Kakizuka A; Ogawa O; Kakehi Y Prostate; 2000 Dec; 45(4):335-40. PubMed ID: 11102959 [TBL] [Abstract][Full Text] [Related]
14. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Wu HC; Hsieh JT; Gleave ME; Brown NM; Pathak S; Chung LW Int J Cancer; 1994 May; 57(3):406-12. PubMed ID: 8169003 [TBL] [Abstract][Full Text] [Related]
16. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. Sato N; Gleave ME; Bruchovsky N; Rennie PS; Goldenberg SL; Lange PH; Sullivan LD J Steroid Biochem Mol Biol; 1996 May; 58(2):139-46. PubMed ID: 8809195 [TBL] [Abstract][Full Text] [Related]
17. LuCaP 35: a new model of prostate cancer progression to androgen independence. Corey E; Quinn JE; Buhler KR; Nelson PS; Macoska JA; True LD; Vessella RL Prostate; 2003 Jun; 55(4):239-46. PubMed ID: 12712403 [TBL] [Abstract][Full Text] [Related]
18. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline. Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404 [TBL] [Abstract][Full Text] [Related]
19. Differential effects of naturally occurring and synthetic organoselenium compounds on biomarkers in androgen responsive and androgen independent human prostate carcinoma cells. Pinto JT; Sinha R; Papp K; Facompre ND; Desai D; El-Bayoumy K Int J Cancer; 2007 Apr; 120(7):1410-7. PubMed ID: 17205524 [TBL] [Abstract][Full Text] [Related]